Based on the higher expression of Gal-1 in T cell-nonexpanders upon anti-PD-1, we investigated whether Gal-1 inhibition could sensitize tumors to PD-1 blockade therapy in established poor T cell-infiltrated 4T1 breast tumors (Figure 7A). The gene discussed is LGALS1; the disease is breast neoplasm.